Plasma beta-amyloid and MRI markers of cerebral small vessel disease Three-City Dijon Study
Neurology. 2014-10-29; 83(22): 2038-2045
DOI: 10.1212/wnl.0000000000001038
Read on PubMed
1. Neurology. 2014 Nov 25;83(22):2038-45. doi: 10.1212/WNL.0000000000001038. Epub
2014 Oct 29.
Plasma β-amyloid and MRI markers of cerebral small vessel disease: Three-City
Dijon study.
Kaffashian S(1), Tzourio C(2), Soumaré A(2), Dufouil C(2), Zhu Y(2), Crivello
F(2), Maillard P(2), Schraen-Maschke S(2), Mazoyer B(2), Buée L(2), Debette S(2).
Author information:
(1)From INSERM U897 (S.K., C.T., A.S., C.D., Y.Z., S.D.), University of Bordeaux,
France; Peking Union Medical College Hospital (Y.Z.), Beijing, China; CNRS-CEA
UMR 5296 (F.C., B.M.), University of Bordeaux, France; University of California
Davis (P.M.); CHRU de Lille (S.S.-M., L.B.), Lille, France; INSERM U837 (S.S.-M.,
L.B.), Lille, France; Department of Neurology (S.D.), Bordeaux University
Hospital, France; Department of Neurology (S.D.), Boston University School of
Medicine, Framingham Heart Study, Boston, MA. .
(2)From INSERM U897 (S.K., C.T., A.S., C.D., Y.Z., S.D.), University of Bordeaux,
France; Peking Union Medical College Hospital (Y.Z.), Beijing, China; CNRS-CEA
UMR 5296 (F.C., B.M.), University of Bordeaux, France; University of California
Davis (P.M.); CHRU de Lille (S.S.-M., L.B.), Lille, France; INSERM U837 (S.S.-M.,
L.B.), Lille, France; Department of Neurology (S.D.), Bordeaux University
Hospital, France; Department of Neurology (S.D.), Boston University School of
Medicine, Framingham Heart Study, Boston, MA.
OBJECTIVE: We investigated the relation of circulating plasma β-amyloid (Aβ) with
MRI markers of small vessel disease (SVD) in dementia-free community persons.
METHODS: Participants were 1,690 individuals aged 65 to 80 years from the
Three-City Dijon Study. Plasma Aβ measurement and MRI examination were performed
at baseline and after a 4-year follow-up. MRI markers of SVD included white
matter hyperintensities (WMH), lacunes, and enlarged perivascular spaces. We
examined the relation of plasma Aβ levels with MRI markers of SVD at baseline and
with progression of WMH over follow-up (n = 1,057). We also assessed whether
these relations were modified by vascular risk factors, notably blood pressure.
RESULTS: Low plasma Aβ1-40 levels were associated with increased progression of
WMH, and low Aβ1-42 with higher odds of extensive WMH progression over the
follow-up (odds ratio = 1.66, 95% confidence interval = 1.16-2.38). Consistently
low Aβ1-40 and Aβ1-42 levels on both measurements were associated with
accelerated progression of WMH. These associations were modified by blood
pressure levels but not the APOE ε4 genotype.
CONCLUSIONS: Progression of WMH volume in dementia-free older persons is
associated with levels of circulating plasma Aβ. These results reinforce the
notion of an interrelation of vascular and neurodegenerative mechanisms in
cerebral aging.
© 2014 American Academy of Neurology.
DOI: 10.1212/WNL.0000000000001038
PMID: 25355827 [Indexed for MEDLINE]